Table 1.
Clinicopathological associations of MCT1&CD163 expression in breast cancer.
| Clinicopathological parameters | CD163 margin | CD163 tissue | MCT1 | MCT1—CD163 margin | MCT1—CD163 Tissue | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| High expression (%) | p | High expression (%) | p | High expression (%) | p | High expression (%) | p | High expression (%) | p | |
| Age at diagnosis, y | 0.333 | 0.645 | 0.298 | 0.350 | 0.750 | |||||
| ≤ 50 | 33 (50) | 10 (58.8) | 29 (49.2) | 22 (46.8) | 6 (50.0) | |||||
| ≥51 | 33 (50) | 7 (41.2) | 30 (50.8) | 25 (53.2) | 6 (50.0) | |||||
| Tumor size (cm) | 0.005 | 0.239 | 0.183 | 0.025 | 0.322 | |||||
| <2 | 17 (25.8) | 4 (23.5) | 18 (30.5) | 11 (23.4) | 3 (25.0) | |||||
| ≥2 | 49 (74.2) | 13 (76.5) | 41 (69.5) | 36 (76.6) | 9 (75.0) | |||||
| Lymph node metastasis | 0.005 | 0.283 | 0.471 | 0.062 | 0.191 | |||||
| Negative | 24 (36.4) | 6 (35.3) | 26 (44.1) | 16 (34.0) | 3 (25.0) | |||||
| Positive | 42 (63.6) | 11 (64.7) | 33 (55.9) | 31 (66.0) | 9 (75.0) | |||||
| Vascular invasion | 0.545 | 0.698 | 0.091 | 0.469 | 0.198 | |||||
| Negative | 59 (89.4) | 15 (88.2) | 51 (86.4) | 40 (85.1) | 10 (83.3) | |||||
| Positive | 7 (10.6) | 2 (11.8) | 8 (13.6) | 7 (14.9) | 2 (16.7) | |||||
| ER | 0.069 | 0.053 | 0.051 | 0.038 | 0.054 | |||||
| Negative | 37 (56.1) | 12 (70.6) | 34 (57.6) | 29 (61.7) | 8 (66.7) | |||||
| Positive | 29 (43.9) | 5 (29.4) | 25 (42.4) | 18 (38.3) | 4 (33.3) | |||||
| PR | 0.006 | 0.004 | 0.004 | 0.002 | 0.002 | |||||
| Negative | 40 (60.6) | 14 (82.4) | 37 (62.7) | 32 (68.1) | 10 (83.3) | |||||
| Positive | 26 (39.4) | 3 (17.6) | 22 (37.3) | 15 (31.9) | 2 (16.7) | |||||
| HER2 | 0.058 | 0.238 | 0.086 | 0.062 | 0.196 | |||||
| Negative | 46 (69.7) | 11 (64.7) | 41 (69.5) | 31 (66.0) | 8 (66.7) | |||||
| Positive | 20 (30.3) | 6 (35.3) | 18 (30.5) | 16 (34.0) | 4 (33.3) | |||||
| Molecular subtypes | 0.004 | 0.038 | 0.088 | 0.007 | 0.001 | |||||
| Luminal A | 10 (16.9) | 14 (21.2) | 1 (5.9) | 23 (48.9) | 10 (83.3) | |||||
| Luminal B | 15 (25.4) | 15 (22.7) | 4 (23.5) | 7 (14.9) | 1 (8.3) | |||||
| HER2 | 10 (16.9) | 10 (15.2) | 4 (23.5) | 4 (8.5) | 0 (0.0) | |||||
| Basal-like | 24 (40.7) | 27 (40.9) | 8 (47.1) | 13 (27.7) | 1 (8.3) | |||||
| Ki67 | 0.002 | 0.006 | 0.000 | 0.000 | 0.000 | |||||
| <14% | 24 (36.4) | 3 (17.6) | 18 (30.5) | 13 (27.7) | 0 (0.0) | |||||
| ≥14% | 42 (63.6) | 14 (82.4) | 41 (69.5) | 34 (72.3) | 12 (100.0) | |||||
| Recurrence | 0.012 | 0.191 | 0.001 | 0.001 | 0.006 | |||||
| No | 38 (57.6) | 9 (52.9) | 31 (52.5) | 23 (48.9) | 5 (41.7) | |||||
| Yes | 28 (42.4) | 8 (47.1) | 28 (47.5) | 24 (51.1) | 7 (58.3) | |||||
*
P-values calculated by Log-rank testing; Bold if statistically significant, P < 0.05. ER, estrogen receptor; PR, progesterone receptor; HER2, human epithelial growth factor receptor-2.